2,4-dichloro-N-phenethylbenzamide | 157729-55-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dichloro-N-phenethylbenzamide
• 英文别名: 2,4-dichloro-N-(2-phenylethyl)benzamide
• CAS: 157729-55-0
• 化学式: C₁₅H₁₃Cl₂NO
• 分子量: 294.18
• InChiKey: SHNULSZFUVUWNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,4-dichloro-N-phenethylbenzamide 在 氯磺酸 作用下， 以 氯仿 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and blood glucose and lipid-lowering effects of benzothiazole-substituted benzenesulfonylurea derivatives

  摘要：

  Sulfonylurea drugs are widely used for the therapy of non-insulin-dependent diabetes mellitus. These drugs improve glucose and lipid levels by stimulating insulin secretion by the pancreatic beta-cell comprising two generations with the second one more potent than the first. Glibenclamide is a well-known and potent second-generation sulfonylurea oral hypoglycemic drug which is most widely used in type II diabetes. In this research, five new analogs were synthesized by exchanging the lipophilic phenyl and urea moieties in the first and the end of the molecule with chlorobenzamide and hydrophilic and antidiabetic aminobenzothiazole substituents. Their glucose and lipid-lowering activities were evaluated and compared to the standard drug. Results showed that all of the new compounds exhibited better activities. In addition, in particular aminomethylbenzothiazoles derivatives could have exerted prominent hypoglycemic and a noticeable hypolipidemic effects superior to glibenclamide.

  DOI：

  10.1007/s00706-015-1471-2
• 作为产物：
  描述：

  2,4-二氯苯甲酸 在 氯化亚砜 、 potassium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2,4-dichloro-N-phenethylbenzamide
  参考文献：
  名称：

  Synthesis and blood glucose and lipid-lowering effects of benzothiazole-substituted benzenesulfonylurea derivatives

  摘要：

  Sulfonylurea drugs are widely used for the therapy of non-insulin-dependent diabetes mellitus. These drugs improve glucose and lipid levels by stimulating insulin secretion by the pancreatic beta-cell comprising two generations with the second one more potent than the first. Glibenclamide is a well-known and potent second-generation sulfonylurea oral hypoglycemic drug which is most widely used in type II diabetes. In this research, five new analogs were synthesized by exchanging the lipophilic phenyl and urea moieties in the first and the end of the molecule with chlorobenzamide and hydrophilic and antidiabetic aminobenzothiazole substituents. Their glucose and lipid-lowering activities were evaluated and compared to the standard drug. Results showed that all of the new compounds exhibited better activities. In addition, in particular aminomethylbenzothiazoles derivatives could have exerted prominent hypoglycemic and a noticeable hypolipidemic effects superior to glibenclamide.

  DOI：

  10.1007/s00706-015-1471-2

文献信息

• Zinc(II)-catalyzed oxidative amidation of arylaldehydes with alkylamines under solvent-free conditions
  作者：Min Zhang、Xiao-Feng Wu

  DOI：10.1016/j.tetlet.2012.12.010

  日期：2013.2

  The first zinc-catalyzed oxidative amidation of arylaldehydes has been developed. Various amides were prepared in good yields under solvent-free and mild reaction conditions. (C) 2012 Elsevier Ltd. All rights reserved.
• Synthesis and blood glucose and lipid-lowering effects of benzothiazole-substituted benzenesulfonylurea derivatives
  作者：Abbas Ahmadi、Mohsen Khalili、Parisa Ghaderi、Ghazale Rastegar、Babak Nahri-Niknafs

  DOI：10.1007/s00706-015-1471-2

  日期：2015.12

  Sulfonylurea drugs are widely used for the therapy of non-insulin-dependent diabetes mellitus. These drugs improve glucose and lipid levels by stimulating insulin secretion by the pancreatic beta-cell comprising two generations with the second one more potent than the first. Glibenclamide is a well-known and potent second-generation sulfonylurea oral hypoglycemic drug which is most widely used in type II diabetes. In this research, five new analogs were synthesized by exchanging the lipophilic phenyl and urea moieties in the first and the end of the molecule with chlorobenzamide and hydrophilic and antidiabetic aminobenzothiazole substituents. Their glucose and lipid-lowering activities were evaluated and compared to the standard drug. Results showed that all of the new compounds exhibited better activities. In addition, in particular aminomethylbenzothiazoles derivatives could have exerted prominent hypoglycemic and a noticeable hypolipidemic effects superior to glibenclamide.